Organization: CQDM

Brain Canada & CQDM fund AbCellera’s cell screening platform technology

AbCellera Biologics Inc and the Univ of British Columbia (UBC) received non-dilutive funding of $1 million from pharma-based consortium CQDM and charitable organization Brain Canada Foundation to advance a discovery platform for next-generation antibody therapeutics. With the additional contribution of $450,000 from AbCellera, the program will leverage AbCellera’s high throughput, single-cell screening platform to allow rapid…

Steve Xanthoudakis

Steve Xanthoudakis has been appointed chief business development officer for CQDM, a non-profit biopharmaceutical research consortium and an industrial research cluster with a mission to fund projects which accelerate the development of drugs. Xanthoudakis has more than 25 years of biopharma experience including senior research scientist and director of global business development & licensing for…

Quebec Budget opens provincial coffers with $834M to stimulate research and innovation

The Quebec government has committed $834 million over five years to research and innovation, including unprecedented increases for post-secondary research after recording its second consecutive Budget surplus. The new funding arrives ahead of the province’s latest research and innovation strategy, due next month, as well as a new life sciences strategy expected before the end of April.

CQDM, Germany partner on novel technologies project

CQDM is partnering with the German Federal Ministry for Economic Affairs and Energy to develop validated tools and chemical probes for the study of protein trafficking and misfolding. Each partner will contribute $500,000 to the initiative, led by McGill Univ‘s Dr David Thomas and Dr Bert Klebl from the Dotrmund-based Lead Discovery Centre. The project…

Six neuroscience teams awarded $8.5 million

CQDM (a Centre of Excellence for Commercialization and Research), Brain Canada and the Ontario Brain Institute have awarded nearly $8.5 million — augmented by $1.5 million in in-kind contributions — to six multi-provincial research teams. The investment will see 33 researchers from academia partnering with smaller companies to develop tools, technologies and platforms that accelerate…

Janssen joins CQDM drug discovery consortium

Janssen Inc (a division of Johnson & Johnson) has become the newest industrial consortium member of CQDM (formerly Quebec Consortium for Drug Discovery). Janssen’s is the ninth pharmaceutical firm to join CQDM in pre-competitive research to develop tools and technologies for accelerating drug discovery. The firm will provide CQDM with cash and in-kind, participate in…

Janssen joins CQDM drug discovery consortium

Janssen Inc (a division of Johnson & Johnson) has become the newest industrial consortium member of CQDM (formerly Quebec Consortium for Drug Discovery). Janssen’s is the ninth pharmaceutical firm to join CQDM in pre-competitive research to develop tools and technologies for accelerating drug discovery. The firm will provide CQDM with cash and in-kind, participate in…